Prevalence of Diabetes Among Hospitalized Patients With Covid-19 in West of Algeria. Identification of Diabetes-related Associated Factors Severe Forms
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Prevalence of diabetes among all hospitalized COVID-19
研究概览
简要总结
By Jan 7, 2020, Chinese scientists had isolated a novel coronavirus, from patients with virus-infected pneumonia. The WHO designated later this virus as COVID-19 (coronavirus disease 2019). This exponential pandemic coronavirus infection is responsible for severe forms in 15 to 20%, for critical ill requiring ventilation in 5% and for mortality in 2%. Algeria was part of the 13 top priority countries identified by WHO based on their direct links and volume of travel to the infected provinces in China.
It is known that some predisposing conditions lead to a worse outcome with coronavirus.
In China, the overall case-fatality rate was 2.3%, but was higher in patients with diabetes (7.3%). In Italy, the most common comorbidities associated with death from COVID-19 were hypertension (73.8%) and diabetes (33.9%). The US Centers for Disease Control and Prevention suggests diabetes is the most common comorbidity in COVID-19 cases. In the largest cohort NHS England study, death from COVID-19 was strongly associated with uncontrolled diabetes (after full adjustment, HR 2.36).
The West Algerian CORODIAB-13 study aims is (1) to assess the prevalence of diabetes among hospitalized patients with Covid-19, (2) to describe the phenotypic characteristics of patients with diabetes, and (3) to identify the parameters specific to the diabetic which are associated with severe forms.
In the future, this study will provide answers for two main questions
- Why diabetics are more at risk of developing Covid-19 infection?
- Why diabetics are at high risk of developing severe forms?
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients admitted in a hospital center since 1th April 2020
- •Patients with COVID19 with biological proof (specific PCR) or with clinical and radiological diagnosis.
- •Patient with diabetes known before the admission
- •New onset diabetes discovered at admission (plasma glycaemia value strictly greater than 2 g/l at any time)
排除标准
- •Active Cancer
- •Minors, adults under guardianship, protected persons
- •Significant disability (The Modified Rankin Scale more than 2 prior admission)
结局指标
主要结局
Prevalence of diabetes among all hospitalized COVID-19
时间窗: 3 months
Assess the prevalence of diabetes among hospitalized patients with Covid-19 in Area of Tlemcen
Diabetes-related factors risk
时间窗: 3 months
Describe the clinical and biological characteristics of hospitalized subjects with diabetes and COVID-19
次要结局
未报告次要终点
研究者
ALI LOUNICI
Chief of Internal Medicine Department
Laboratoire De Recherche Sur Le Diabete, Université de Tlemcen